Healthcare >> CEO Interviews >> October 19, 2009
Dr. Paul H. Fischer, Ph.D., has served as President, Chief Executive Officer and a Director of GenVec, Inc., since 1996. Prior to joining GenVec, he was Executive Vice President of Research and Development with Oncologix, Inc. - now Antigenics, Inc. - a biotechnology company. Previously he served as Manager, Cancer Research, at Pfizer, Inc. Dr. Fischer received his B.S. in biology from the University of Denver and his Ph.D. in pharmacology from the University of California at San Francisco. He performed his post-doctoral research in pharmacology at Yale University School of Medicine. Prior to joining Pfizer, he also served as an Assistant Professor of pharmacology at the University of Missouri School of Medicine and an Associate Professor of human oncology at the University of Wisconsin. Dr. Fischer serves on numerous community, academic, and professional organizations and boards. Profile
TWST: Tell us a little bit about GenVec.
Dr. Fischer: GenVec (GNVC) was founded in 1992 to explore the potential of gene-based medicines, which was a very forward-looking concept back then. From the
